StockNow
Log in
Global Markets

AstraZeneca (AZN LN) guides FY26 GM to be stable to slightly higher than 2025; H2 margin should decline vs. H1 due to the seasonal mix of lower-margin FluMist and Beyfortus sales

StockNow breaking-news AI analysis

AstraZeneca expects stable FY26 gross margins versus 2025, but anticipates a seasonal H2 decline due to higher volumes of lower-margin seasonal products like FluMist and Beyfortus.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Pakistani sources say Pakistan PM Sharif and Army Chief Munir will visit Saudi Arabia tomorrow, Al Hadath reports

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)